Cite
APA Citation
Tatman, P., Wroblewski, T., Fringuello, A., Scherer, S., Foreman, W., Damek, D., Youssef, S., Lillehei, K., Ormond, D., & Graner, M. (2021). dDRE-43. SCREENING OF FDA-APPROVED COMPOUNDS FOR THE TREATMENT OF CHORDOMA, WITH IN VIVO VALIDATION USING THREE DIFFERENT XENOGRAFT MODELS, IDENTIFIES BRIGATINIB AS A POTENTIAL TREATMENT. Neuro-oncology, 23, vi83–vi84. http://access.bl.uk/ark:/81055/vdc_100146090306.0x000013